Providence Swedish Neuroscience Institute (PSNI) Reaches Milestone in Reducing Global Burden of Glioblastoma

Jul 14, 2026 | In the News

Click here to view...

A New Approach to Treating Brain Cancer: HDT Bio Launches Canadian Clinical Program at McGill University

Jul 14, 2026 | Press Releases, Uncategorized

KING5 Seattle Healthlink Feature: Seattle-based group testing new immunotherapy approach to treat deadly form of brain cancer

Jul 10, 2026 | In the News

HDT Bio and UTMB Receive MCDC Innovation Prototype Award for Advancing CCHF Vaccine from Lab to Phase 1 Clinical Trial

May 21, 2026 | Press Releases

SEATTLE, May 21, 2026 /PRNewswire/ — HDT Bio, a clinical-stage biotechnology company based in Seattle, Washington, today announced that it received the Medical CBRN Defense Consortium (MCDC) Innovation Prototype Award. The award recognizes HDT Bio’s MCDC...

FDA Greenlights HDT Bio’s First-in-Class HDT-321 for the Prevention of Deadly Tick-Borne Disease

Sep 22, 2025 | Press Releases

SEATTLE, Sept. 19, 2025 /PRNewswire/ — HDT Bio Corporation, a U.S.-based clinical-stage biotechnology company advancing immune-enhancing solutions for global health, biodefense, and oncology, today announced that the U.S. Food and Drug Administration (FDA) has...